Research & Development
C2N Diagnostics launching next-generation blood test for Alzheimer's disease detection
With an anticipated launch in the first quarter of 2023, the PrecivityAD2 blood test would facilitate earlier diagnosis of Alzheimer's disease pathology than is possible with current tests, the firm said.
November 29, 2022
Blood-based MDx test developer DiamiR to present poster on trial findings at CTAD
The poster will be presented during the session “Clinical trials: Biomarkers including plasma” during the 15th Clinical Trials on Alzheimer’s Disease (CTAD) in San Francisco from November 29 to December 2.
November 28, 2022
Alzheimer’s study compares blood-based biomarkers, other detection technologies
The Global Alzheimer’s Platform Foundation technology study, with more than 1,000 participants, focuses on access and diversity.
November 15, 2022
NanoMosaic obtains rights to biomarker test for the diagnosis, prognosis of anesthesia-induced delirium, Alzheimer's
The test uses the Tessie system to alleviate bottlenecks in proteomics analysis and to enable protein interrogation as well as multiomics analysis within a single chip during one run.
October 12, 2022
Diadem nabs $2.5M to further validate Alzheimer’s blood test
The two-year grant will enable Diadem, a company that has been developing a blood-based test for the early prediction of Alzheimer's disease (AD), to leverage data from the Alzheimer's Disease Neuroimaging Initiative (ADNI), a longitudinal multicenter study designed to enable development of biomarkers for the early detection and tracking of AD.
September 6, 2022
Roche nabs FDA breakthrough designation for Alzheimer’s Dx
The panel, a blood-based biomarker test, is intended to be used in conjunction with other clinical information in symptomatic patients who are being evaluated for Alzheimer's disease and other causes of cognitive decline.
July 18, 2022
DNA forensic evidence frees Ohio man of rape, attempted rape
‘Good’ cholesterol worse for some adults: NIH study
Empatica receives FDA clearance for digital biomarker platform, closes Series B financing
Chembio Diagnostics applies for FDA CLIA waiver for HIV, syphilis test
Dr. Fauci invokes Yogi Berra to describe emerging infectious disease challenge
AnchorDx enrolling U.S. clinical trial for bladder cancer assay
Alzheimer’s test developer Diadem joins DPUK
Diadem's AlzoSure Predict blood test identifies signs of cognitive impairment that will or will not progress to Alzheimer's dementia up to six years before diagnosis.
June 12, 2022
Diadem highlights new study on AlzoSure test for Alzheimer's
In a retrospective study published online May 17 in the Journal of Prevention of Alzheimer's Disease, researchers reported that AlzoSure Predict achieved an area under the curve (AUC) of more than 0.98 for identifying people who would progress to future symptomatic Alzheimer's disease up to six years before diagnosis.
May 17, 2022
New biomarker could detect early Alzheimer’s before symptoms
In addition, the findings have some implications for taking brain-boosting dietary supplements that contain the amino acid serine. The key compound responsible for producing serine in the body is PHGDH. The scientists reported that PHGDH mRNA and protein levels had increased in the brains of two mouse models of Alzheimer's disease or tauopathy.
May 4, 2022
FDA grants approval for Fujirebio assay for Alzheimer's plaques
The FDA granted clearance under its breakthrough device pathway to Fujirebio's Lumipulse G β-Amyloid Ratio (1-42/1-40) test, which is designed to measure the ratio of β-amyloid 1-42 and β-amyloid 1-40. These are proteins that can accumulate and form plaques in the brain; concentrations of these proteins can be detected in cerebral spinal fluid (CSF).
May 3, 2022
Quest publishes Alzheimer’s report, unveils blood test
The report, called "The Coming Alzheimer's Disease Healthcare Revolution: U.S. Physician and Adult Perspectives on the Future of Diagnostics and Treatment," found that 66% of physicians believe that "we are on the precipice of groundbreaking new treatment options" for Alzheimer's disease, according to Quest.
May 3, 2022
Does race affect interpretation of Alzheimer's disease tests?
An international team led by researchers at Washington University School of Medicine in St. Louis, MO, compared three experimental blood tests and a commercially available Alzheimer's disease test they developed in previous work (PrecivityAD, C2N Diagnostics) in 76 pairs of Black and non-Hispanic white participants.
April 21, 2022
Page 1 of 4